Laurus Labs Funds Expansion of KRKA Joint Venture

Laurus Labs will invest up to EUR 9.8 million in its joint venture, KRKA Pharma Private Limited. KRKA d.d. will co-invest EUR 10.2 million, maintaining the 51:49 shareholding.

Funding Approved for New Facility

Laurus Labs' Board of Directors has approved an additional investment of up to EUR 9.8 million in KRKA Pharma Private Limited, its joint venture. This money will fund KRKA Pharma's plan to build a new manufacturing facility.

KRKA d.d., the co-venturer, will also invest EUR 10.2 million, ensuring the existing 51:49 shareholding ratio is maintained. The investment is projected to be completed during the financial year 2026-27. KRKA Pharma Private Limited was incorporated on April 12, 2024.

Strategic Expansion Drivers

This investment shows Laurus Labs' commitment to growing its pharmaceutical business. The new factory will boost the JV's production ability, helping it enter new markets and supporting Laurus Labs' long-term goals.

Joint Venture Background

Laurus Labs, founded in 2005, is a research-driven pharmaceutical and biotechnology company focusing on APIs, formulations, and CDMO services. It established the joint venture Krka Pharma Pvt. Ltd. with Slovenia-based KRKA d.d. in Hyderabad, India, aiming to produce finished pharmaceutical products for new markets, including India.

An earlier investment phase, approved in March 2025, involved ₹833 crore from Laurus Labs and ₹867 crore from KRKA d.d. to secure land and commence facility setup.

Key Impacts of the Investment

• Enhanced production capacity for KRKA Pharma Private Limited.
• Support for KRKA Pharma's capital expenditure and facility establishment.
• Better alignment for Laurus Labs' JV operations.
• Stable shareholding structure maintained at 51% (KRKA d.d.) and 49% (Laurus Labs).
• Potential for increased market penetration in India and other emerging markets.

Regulatory Considerations

The investment needs approval under SEBI Listing Regulations for related party transactions. It is being conducted at arm's length and will be monitored.

Competitive Landscape

Laurus Labs operates in a competitive pharmaceutical landscape alongside major players like Divi's Laboratories and Dr. Reddy's Laboratories, which are also significant API manufacturers. Syngene International is another key competitor in integrated R&D and manufacturing services. These companies compete on quality, cost, regulatory compliance, and innovation, while many also engage in strategic collaborations or JVs to expand their market reach and capabilities.

Projected Financials

• KRKA Pharma Private Limited's projected turnover for the financial year 2025-26 is INR 10.47 million.

Next Steps for Investors

• Monitor the completion of the additional EUR 9.8 million investment by FY 2026-27.
• Track the progress of the new manufacturing facility setup by KRKA Pharma.
• Observe any further updates on the JV's market entry and operational milestones.
• Note any regulatory disclosures or progress reports related to the investment and facility construction.